Key result
The mRNA-1273 vaccine was evaluated for its efficacy against the Delta variant by assessing the incidence of infection during the open-label phase of a phase 3 trial.
Key points are not available for this paper at this time.
Population
Participants who had received placebo in a previous phase of the trial
Comparison
mRNA-1273 vaccine offered in the open-label phase
Design
Open-label phase of a trial
Answers are grounded in this paper and cite their sources.
Informs mRNA-1273 performance vs Delta in open-label follow-up; extends phase 3 data to variant-specific protection.
mRNA-1273 Vaccine Efficacy against the Delta Variant Participants who had received placebo in a previous phase of this trial were offered the mRNA-1273 vaccine in the open-label phase.
No takes yet. Share an insight, caveat, or question.
Baden et al. (2021) studied this question. The mRNA-1273 vaccine was evaluated for its efficacy against the Delta variant by assessing the incidence of infection during the open-label phase of a phase 3 trial.
Synapse has enriched 10 related papers. Consider them for comparative context: